CDMO Services Brochure

Neuland Laboratories Limited has entered into a development collaboration with LIR Life Sciences Corp to advance a novel transdermal GLP-1/GIP therapy platform for obesity. The partnership highlights Neuland’s growing expertise in peptide development and manufacturing, supporting the development of innovative cell-penetrating peptide (CPP) technologies designed to enable non-invasive drug delivery.

Neuland Laboratories is expanding its process development capabilities with a new $20 million (₹189 crore) dedicated Process Development Centre in Hyderabad. Designed exclusively for process development and integrated scale-up activities, the 135,000 sq. ft. facility will house over 500 scientists and strengthen Neuland’s ability to accelerate development timelines, improve scale-up readiness, and support complex API and peptide programs from early development through commercialization.